PTGX vs. DVAX, TARO, ZLAB, HRMY, AVDL, SUPN, ARDX, AMRX, EWTX, and DAWN
Should you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dynavax Technologies (DVAX), Taro Pharmaceutical Industries (TARO), Zai Lab (ZLAB), Harmony Biosciences (HRMY), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Ardelyx (ARDX), Amneal Pharmaceuticals (AMRX), Edgewise Therapeutics (EWTX), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical preparations" industry.
Protagonist Therapeutics (NASDAQ:PTGX) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
Protagonist Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are held by institutional investors. 5.0% of Protagonist Therapeutics shares are held by insiders. Comparatively, 3.0% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Dynavax Technologies received 206 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 65.77% of users gave Dynavax Technologies an outperform vote while only 59.54% of users gave Protagonist Therapeutics an outperform vote.
Protagonist Therapeutics has a net margin of 0.00% compared to Dynavax Technologies' net margin of -2.75%. Dynavax Technologies' return on equity of -1.08% beat Protagonist Therapeutics' return on equity.
In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 3 articles in the media. Dynavax Technologies' average media sentiment score of 0.73 beat Protagonist Therapeutics' score of 0.61 indicating that Dynavax Technologies is being referred to more favorably in the news media.
Protagonist Therapeutics presently has a consensus target price of $36.00, suggesting a potential upside of 43.14%. Dynavax Technologies has a consensus target price of $25.00, suggesting a potential upside of 123.02%. Given Dynavax Technologies' higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Protagonist Therapeutics.
Dynavax Technologies has higher revenue and earnings than Protagonist Therapeutics. Dynavax Technologies is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Dynavax Technologies beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Protagonist Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagonist Therapeutics Competitors List
Related Companies and Tools
